Results from a recent study presented at the European League Against Rheumatism Annual European Congress of Rheumatology showed that patients with lupus nephritis (LN) who are positive for anti-Sm antibodies may be more likely to require immunosuppressive therapy. Lupus nephritis (LN) is kidney inflammation caused by systemic lupus erythematosus (SLE…
A newly published study, titled, “Medication nonadherence is associated with increased subsequent acute care utilization among medicaid beneficiaries with systemic lupus erythematosus” in the journal Arthritis Care & Research, suggests SLE patients with poor medication compliance were more likely to experience emergency room visits and hospitalizations compared…
Recent research has shed light on the high probability of patients with Systemic Lupus Erythematosus (SLE) developing thyroid dysfunction. According to recently published results from 167 patients with SLE who were evaluated for serum free levels of the thyroid hormones T3, T4 and Thyroid Stimulating Hormones (TSH), 119 were found to…
Scientists at Stanford University School of Medicine have recently developed a groundbreaking technology that can help shed more light on the countless genetic molecules that can switch from active to inactive throughout an individual’s lifespan, much like switches. The study was titled, “Individuality and Variation of Personal…
According to a recent press release from UCB, a global biopharma company, results from its Phase 3 clinical trials in patients with systemic lupus erythematosus (SLE) revealed that Epratuzumab did not meet its primary efficacy endpoint. A total of 786 and 788 patients with SLE took part…
Professionally, Chloe Barlow is an attorney at law, but after receiving a diagnosis of lupus, she rekindled her childhood love for writing as a means to cope with her illness. “I first started having symptoms when I was 12, but they were always very mysterious,” said Chloe in the…
The second most common experience of patients with newly onset systemic lupus erythematosus (SLE) was found to be mood disorders, with roughly one third of the occurrences related to the disease. The finding came from a recent study led by John Hanly and presented during the European League Against Rheumatism Annual European Congress of Rheumatology…
The Chinese Academy of Sciences (CAS) recently announced that Chinese investigators are going to test a new drug agent for treating lupus in upcoming clinical trials. The compound called SM934, is a water-soluble artemisinin derivative that has already been approved by the China Food and Drug Administration. According to the CAS, over the last…
Seattle Genetics, Inc., a biotechnology company that specializes in the development and commercialization of novel antibody-based therapies for the treatment of cancer, has officially begun a Phase II clinical study designed to test ADCETRIS (brentuximab vedotin) as a treatment for systemic lupus erythematosus (SLE). This drug candidate is an antibody-drug conjugate (ADC) that…
Pediatric Rheumatology Fellow at Albert Einstein College of Medicine of Yeshiva University and Children’s Hospital at Montefiore, Dr. Tamar Rubinstein, recently received the Lupus Foundation of America’s third yearly Career Development Award. “Now, more than ever, it is essential that young, energetic investigators receive funding for vital lupus research,” said…